BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Xie Z, Zhao J, Wang H, Jiang Y, Yang Q, Fu Y, Zeng H, Hölscher C, Xu J, Zhang Z. Magnolol alleviates Alzheimer's disease-like pathology in transgenic C. elegans by promoting microglia phagocytosis and the degradation of beta-amyloid through activation of PPAR-γ. Biomed Pharmacother 2020;124:109886. [PMID: 32000045 DOI: 10.1016/j.biopha.2020.109886] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
Number Citing Articles
1 Tang Y, Wang L, Yi T, Xu J, Wang J, Qin J, Chen Q, Yip K, Pan Y, Hong P, Lu Y, Shen H, Chen H. Synergistic effects of autophagy/mitophagy inhibitors and magnolol promote apoptosis and antitumor efficacy. Acta Pharmaceutica Sinica B 2021;11:3966-82. [DOI: 10.1016/j.apsb.2021.06.007] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Paul D, Chipurupalli S, Justin A, Raja K, Mohankumar SK. Caenorhabditis elegans as a possible model to screen anti-Alzheimer's therapeutics. J Pharmacol Toxicol Methods 2020;106:106932. [PMID: 33091537 DOI: 10.1016/j.vascn.2020.106932] [Reference Citation Analysis]
3 Lin Y, Li Y, Zeng Y, Tian B, Qu X, Yuan Q, Song Y. Pharmacology, Toxicity, Bioavailability, and Formulation of Magnolol: An Update. Front Pharmacol 2021;12:632767. [PMID: 33815113 DOI: 10.3389/fphar.2021.632767] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Dhage PA, Sharbidre AA, Dakua SP, Balakrishnan S. Leveraging hallmark Alzheimer's molecular targets using phytoconstituents: Current perspective and emerging trends. Biomed Pharmacother 2021;139:111634. [PMID: 33965726 DOI: 10.1016/j.biopha.2021.111634] [Reference Citation Analysis]
5 Yang Z, Zhou DD, Huang SY, Fang AP, Li HB, Zhu HL. Effects and mechanisms of natural products on Alzheimer's disease. Crit Rev Food Sci Nutr 2021;:1-21. [PMID: 34613845 DOI: 10.1080/10408398.2021.1985428] [Reference Citation Analysis]
6 Xie Z, Li E, Gao G, Du Y, Wang M, Wang H, Wang P, Qiao Y, Su Y, Xu J, Zhang X, Zhang Z. Zexie Tang targeting FKBP38/mTOR/SREBPs pathway improves hyperlipidemia. Journal of Ethnopharmacology 2022. [DOI: 10.1016/j.jep.2022.115101] [Reference Citation Analysis]
7 Navarro-hortal MD, Romero-márquez JM, Osta S, Jiménez-trigo V, Muñoz-ollero P, Varela-lópez A. Natural Bioactive Products and Alzheimer’s Disease Pathology: Lessons from Caenorhabditis elegans Transgenic Models. Diseases 2022;10:28. [DOI: 10.3390/diseases10020028] [Reference Citation Analysis]
8 Zhu G, Fang Y, Cui X, Jia R, Kang X, Zhao R. Magnolol upregulates CHRM1 to attenuate Amyloid-β-triggered neuronal injury through regulating the cAMP/PKA/CREB pathway. J Nat Med 2021. [PMID: 34705126 DOI: 10.1007/s11418-021-01574-2] [Reference Citation Analysis]
9 Tao C, Chen J, Huang X, Chen Z, Li X, Li Y, Xu Y, Ma M, Wu Z. CT1-3, a novel magnolol-sulforaphane hybrid suppresses tumorigenesis through inducing mitochondria-mediated apoptosis and inhibiting epithelial mesenchymal transition. Eur J Med Chem 2020;199:112441. [PMID: 32416457 DOI: 10.1016/j.ejmech.2020.112441] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Xian YF, Qu C, Liu Y, Ip SP, Yuan QJ, Yang W, Lin ZX. Magnolol Ameliorates Behavioral Impairments and Neuropathology in a Transgenic Mouse Model of Alzheimer's Disease. Oxid Med Cell Longev 2020;2020:5920476. [PMID: 32714487 DOI: 10.1155/2020/5920476] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
11 Govindarajulu M, Ramesh S, Neel L, Fabbrini M, Buabeid M, Fujihashi A, Dwyer D, Lynd T, Shah K, Mohanakumar KP, Smith F, Moore T, Dhanasekaran M. Nutraceutical based SIRT3 activators as therapeutic targets in Alzheimer's disease. Neurochem Int 2021;144:104958. [PMID: 33444675 DOI: 10.1016/j.neuint.2021.104958] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
12 Xie Z, Gao G, Wang H, Li E, Yuan Y, Xu J, Zhang Z, Wang P, Fu Y, Zeng H, Song J, Hölscher C, Chen H. Dehydroabietic acid alleviates high fat diet-induced insulin resistance and hepatic steatosis through dual activation of PPAR-γ and PPAR-α. Biomed Pharmacother 2020;127:110155. [PMID: 32413669 DOI: 10.1016/j.biopha.2020.110155] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
13 Lago-Fernandez A, Zarzo-Arias S, Jagerovic N, Morales P. Relevance of Peroxisome Proliferator Activated Receptors in Multitarget Paradigm Associated with the Endocannabinoid System. Int J Mol Sci 2021;22:1001. [PMID: 33498245 DOI: 10.3390/ijms22031001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
14 Yu CP, Li PY, Chen SY, Lin SP, Hou YC. Magnolol and Honokiol Inhibited the Function and Expression of BCRP with Mechanism Exploration. Molecules 2021;26:7390. [PMID: 34885972 DOI: 10.3390/molecules26237390] [Reference Citation Analysis]
15 Calfio C, Gonzalez A, Singh SK, Rojo LE, Maccioni RB. The Emerging Role of Nutraceuticals and Phytochemicals in the Prevention and Treatment of Alzheimer's Disease. J Alzheimers Dis 2020;77:33-51. [PMID: 32651325 DOI: 10.3233/JAD-200443] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 11.0] [Reference Citation Analysis]
16 Zhang J, Liu Y, Wang S, Que R, Zhao W, An L. Exploration of the Molecular Mechanism for Lipoprotein Lipase Expression Variations in SH-SY5Y Cells Exposed to Different Doses of Amyloid-Beta Protein. Front Aging Neurosci 2020;12:132. [PMID: 32477101 DOI: 10.3389/fnagi.2020.00132] [Reference Citation Analysis]
17 Md S, Alhakamy NA, Alfaleh MA, Afzal O, Altamimi ASA, Iqubal A, Shaik RA. Mechanisms Involved in Microglial-Interceded Alzheimer's Disease and Nanocarrier-Based Treatment Approaches. J Pers Med 2021;11:1116. [PMID: 34834468 DOI: 10.3390/jpm11111116] [Reference Citation Analysis]
18 Terzo S, Amato A, Mulè F. From obesity to Alzheimer's disease through insulin resistance. J Diabetes Complications 2021;35:108026. [PMID: 34454830 DOI: 10.1016/j.jdiacomp.2021.108026] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
19 Ramli NZ, Yahaya MF, Tooyama I, Damanhuri HA. A Mechanistic Evaluation of Antioxidant Nutraceuticals on Their Potential against Age-Associated Neurodegenerative Diseases. Antioxidants (Basel) 2020;9:E1019. [PMID: 33092139 DOI: 10.3390/antiox9101019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
20 Jiang X, He H, Mo L, Liu Q, Yang F, Zhou Y, Li L, Su D, Yi S, Zhang J. Mapping the Plasticity of Morphology, Molecular Properties and Function in Mouse Primary Microglia. Front Cell Neurosci 2022;15:811061. [DOI: 10.3389/fncel.2021.811061] [Reference Citation Analysis]
21 Santos J, Quimque MT, Liman RA, Agbay JC, Macabeo APG, Corpuz MJ, Wang YM, Lu TT, Lin CH, Villaflores OB. Computational and Experimental Assessments of Magnolol as a Neuroprotective Agent and Utilization of UiO-66(Zr) as Its Drug Delivery System. ACS Omega 2021;6:24382-96. [PMID: 34604621 DOI: 10.1021/acsomega.1c02555] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Qiao O, Ji H, Zhang Y, Zhang X, Zhang X, Liu N, Huang L, Liu C, Gao W. New insights in drug development for Alzheimer's disease based on microglia function. Biomed Pharmacother 2021;140:111703. [PMID: 34083109 DOI: 10.1016/j.biopha.2021.111703] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]